Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Meds A-Z

Atipamezole

Detailed information about Atipamezole

Official label facts Owner quick guide first Marketing clearly labeled
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Reviewed / Updated / Sources

Reviewed: Not available

Updated: February 12, 2026, 10:44 PM UTC

Sources:

Pet Owner Quick Guide

Start here first for the simple next-step summary.

Used for:

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

What to watch for:

  • For intramuscular use only
  • Not recommended for use in pregnant or lactating animals, or animals intended for breeding
  • Atipamezole has not been evaluated in breeding animals
  • very low energy (1 reports)
  • Lameness (1 reports)
  • Lack of efficacy - NOS (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Safety & side effects

What to watch:

  • For intramuscular use only
  • Not recommended for use in pregnant or lactating animals, or animals intended for breeding
  • Atipamezole has not been evaluated in breeding animals
  • very low energy
  • Lameness

Most reported reactions:

  • Tiredness (lethargy) (1 reports)
  • Lameness (1 reports)
  • Lack of efficacy - NOS (1 reports)

When to call your vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Data freshness: source data appears current.

Latest refresh: Mar 21, 2026, 10:03 a.m.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Mar 3, 2026, 11:00 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 21, 2026, 10:03 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:21 AM UTC
Image coming soon
Atipamezole

Atipamezole

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: Not available (source)

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Not available
Form: Liquid (Solution), Sterile Injectable Solution
Identifiers:
ANADA: 200624 ANADA: 200753 ANADA: 200772 ANADA: 200838 NADA: 141033 NDC Package: 11695-7020-1 NDC Package: 15914-008-01 NDC Package: 43744-021-01 NDC Package: 46066-109-13 NDC Package: 54771-6293-1 NDC Package: 64189-0001-0 NDC Package: 64189-0001-1 NDC Package: 68504-007-01 NDC Package: 69043-039-10 NDC Package: 71052-191-10 NDC Package: 71052-191-25 NDC Package: 71052-191-50 NDC Package: 71052-192-10 NDC Package: 71052-192-25 NDC Package: 71052-192-50
Source metadata:

Warnings / Contraindications

For intramuscular use only. Not recommended for use in pregnant or lactating animals, or animals intended for breeding. Atipamezole has not been evaluated in breeding animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: For intramuscular use only. Not recommended for use in pregnant or lactating animals, or animals intended for breeding. Atipamezole has not been evaluated in breeding animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
26
Species represented
2
Grouped by Body System
Digestive (3) · Drooling, Diarrhea, Decreased appetite Skin & allergy (1) · Application site hair loss Neurologic (1) · Tiredness (lethargy) Effectiveness (1) · Lack of efficacy - NOS Other (26) · Lameness, Intentional misuse, Hypochloraemia
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Dog 1
Other 1 Dog 1
Effectiveness 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (24) Cat (8)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Dog Serious - 1
Other Dog Serious - 1
Effectiveness Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Digestive Cat Non-serious - 1
Digestive Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Skin & allergy Cat Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents are grouped for faster access.

Owner handouts (0)
  • No owner handouts linked yet.
Official label / PI (0)
  • No official label or package insert links yet.
SPL (5)
  • Atipamezole Hydrochloride Injection · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18406/Atipamezole%20Hydrochloride%20Injection
  • CONTRASED™ · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/15345/CONTRASED%E2%84%A2
  • Cropamezole™ · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/14481/Cropamezole%E2%84%A2
  • REVERTIDINE™ · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/3416/REVERTIDINE%E2%84%A2
  • Antisedan® · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1833/Antisedan%C2%AE
FOI (6)
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Mar 3, 2026, 11:00 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 21, 2026, 10:03 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:21 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Antisedan® Atipamezole Hydrochloride Injection CONTRASED™ Cropamezole™ REVERTIDINE™
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Liquid (Solution), Sterile Injectable Solution • Intramuscular
Applications: ANADA 200-838 • ANADA 200-772 • ANADA 200-753 • ANADA 200-624 • NADA 141-033
Documents: 6 (FOI: 6) • SPL: 5 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 21 • Cat 17 • View
Case summaries: 10 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • For intramuscular use only. Not recommended for use in pregnant or lactating animals, or animals intended for breeding. Atipamezole has not been evaluated in breeding animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Tiredness (lethargy) (1) Lameness (1) Lack of efficacy - NOS (1) Intentional misuse (1) Hypochloraemia (1) Hyperphosphataemia (1) Haematemesis (1) Eosinopenia (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200624 ANADA: 200753 ANADA: 200772 ANADA: 200838 NADA: 141033 NDC Package: 11695-7020-1 NDC Package: 15914-008-01 NDC Package: 43744-021-01 NDC Package: 46066-109-13 NDC Package: 54771-6293-1 NDC Package: 64189-0001-0 NDC Package: 64189-0001-1 NDC Package: 68504-007-01 NDC Package: 69043-039-10 NDC Package: 71052-191-10 NDC Package: 71052-191-25 NDC Package: 71052-191-50 NDC Package: 71052-192-10 NDC Package: 71052-192-25 NDC Package: 71052-192-50 NDC Package: 86136-106-31 NDC Package: 86136-115-31 NDC Package: 86136-151-31 NDC Package: 86184-006-01
Package NDC Product NDC Form / Route Status
11695-7020-1 11695 -
15914-008-01 15914 -
43744-021-01 43744 -
46066-109-13 46066 -
54771-6293-1 54771 -
64189-0001-0 64189 -
64189-0001-1 64189 -
68504-007-01 68504 -
69043-039-10 69043 -
71052-191-10 71052 -
71052-191-25 71052 -
71052-191-50 71052 -
71052-192-10 71052 -
71052-192-25 71052 -
71052-192-50 71052 -
86136-106-31 86136 -
86136-115-31 86136 -
86136-151-31 86136 -
86184-006-01 86184 -
86197-002-01 86197 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 9 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: For intramuscular use only. Not recommended for use in pregnant or lactating animals, or animals intended for breeding. Atipamezole has not been evaluated in b… (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Injection site swelling, Diarrhoea, Vomiting, Lethargy (see also Central nervous system depression in… (Official, 2026-02-12)
  • usage: For reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride or medetomidine hydrochloride. For the reversal of the sedative and analges… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Atipamezole Hydrochloride Injection
RX
Atipamezole Hydrochloride
Sterile Injectable Solution • Intramuscular
Label highlights
Official documents
Felix Pharmaceuticals Pvt. Ltd. ANADA 200-838 Approved Mar 2, 2026
CONTRASED™
RX
Atipamezole Hydrochloride
Sterile Injectable Solution • Intramuscular
Label highlights
Official documents
Parnell Technologies Pty. Ltd. ANADA 200-772 Approved Nov 26, 2024
Cropamezole™
RX
Atipamezole Hydrochloride
Sterile Injectable Solution • Intramuscular
Label highlights
Official documents
Cronus Pharma Specialities India Private Ltd. ANADA 200-753 Approved Aug 1, 2023
REVERTIDINE™
RX
Atipamezole Hydrochloride
Sterile Injectable Solution • Intramuscular
Label highlights
Official documents
Modern Veterinary Therapeutics, LLC ANADA 200-624 Approved Aug 2, 2018
Antisedan®
RX
Atipamezole Hydrochloride
Liquid (Solution) • Intramuscular
Label highlights
Official documents
Orion Corp. NADA 141-033 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications
5.0 mg atipamezole hydrochloride/mL
Dogs
Indication

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

Dosage

Administer 3,750 mcg/m2 intramuscularly for the reversal of intravenous dexmedetomidine hydrochloride or medetomidine hydrochloride and 5,000 mcg/m2 intramuscularly for the reversal of intramuscular dexmedetomidine hydrochloride or medetomidine hydrochloride.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
5 mg/mL
Dogs
Indication

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

Dosage

Administer intramuscularly (IM) for reversal of sedation and analgesia regardless of the route used for dexmedetomidine hydrochloride or medetomidine hydrochloride. The atipamezole dose for the reversal of intravenous dexmedetomidine hydrochloride or medetomidine hydrochloride is 3750 mcg/m2. The atipamezole dose for the reversal of IM dexmedetomidine hydrochloride or medetomidine hydrochloride is 5000 mcg/m2.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
5 mg/mL
Dogs
Indication

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

Dosage

Administer 3750 mcg/m2 intramuscularly for the reversal of intravenous dexmedetomidine hydrochloride or medetomidine hydrochloride and 5000 mcg/m2 intramuscularly for the reversal of intramuscular dexmedetomidine hydrochloride or medetomidine hydrochloride.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
5.0 mg/mL
Dogs
Indication

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

Dosage

REVERTIDINE™ is administered intramuscularly (IM) for reversal of sedation and analgesia regardless of the route used for dexmedetomidine or medetomidine. The atipamezole dose for the reversal of IV dexmedetomidine or medetomidine is 3750 mcg/m2.

The atipamezole dose for the reversal of IM dexmedetomidine or medetomidine is 5000 mcg/m2.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each milliliter of sterile injectable solution contains 5.0 milligrams of atipamezole hydrochloride.
Dogs
Indication
For reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride or medetomidine hydrochloride.
Dosage
The atipamezole dose for the reversal of intravenous (IV) DEXDOMITOR (dexmedetomidine hydrochloride), or DOMITOR (medetomidine hydrochloride) is 3750 mcg/m2. The atipamezole dose for the reversal of intramuscular (IM) DEXDOMITOR (dexmedetomidine hydrochloride), or DOMITOR (medetomidine hydrochloride) is 5000 mcg/m2.
Limitations
For intramuscular use only. Not recommended for use in pregnant or lactating animals, or animals intended for breeding. Atipamezole has not been evaluated in breeding animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    An additional indication for the reversal of the sedative and analgesic effects of DEXDOMITOR (dexmedetomidine hydrochloride).
  • Summary
    ANTISEDAN ® is indicated for the reversal of the clinical effects of the sedative and analgesic agent, DOMITOR® (medetomidine hydrochloride), in dogs.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

For reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride or medetomidine hydrochloride. For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

For intramuscular use only. Not recommended for use in pregnant or lactating animals, or animals intended for breeding. Atipamezole has not been evaluated in breeding animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Drooling (1) • Cat Diarrhea (1) • Dog Decreased appetite (1) • Dog

Showing top 5 for Digestive.

Skin & allergy
Application site hair loss (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic
Tiredness (1) • Dog

Showing top 5 for Neurologic.

Effectiveness
Lack of efficacy - NOS (1) • Dog

Showing top 5 for Effectiveness.

Other
Lameness (1) • Dog Intentional misuse (1) • Cat Hypochloraemia (1) • Dog Hyperthermia (1) • Cat Hyperphosphataemia (1) • Dog
Show more (21)
Hyperglycaemia (1) • Cat Hyperactivity (1) • Cat Haematemesis (1) • Dog Eosinopenia (1) • Dog Elevated temperature (1) • Dog Elevated serum alkaline phosphatase (1) • Dog Elevated creatinine (1) • Dog Elevated alanine aminotransferase (1) • Dog Dysphoria (1) • Cat Dull (1) • Dog Dry mucous membrane (1) • Dog Dehiscence (1) • Dog Decreased haematocrit (1) • Dog Decreased blood urea nitrogen (BUN) or creatinine (1) • Cat Death (1) • Dog Bruising (1) • Dog Bradycardia (1) • Dog Bacterial skin infection NOS (1) • Dog Application site pain (1) • Dog Application site discharge NOS (1) • Dog Application site bleeding (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Cat, Domestic Shorthair, Male, 5 year, 8.61 kilogram • Drug: MSK, Unknown • Reactions: Hyperthermia, Hyperactivity • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055972
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 5.00 Year
  • Weight: 8.610 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Hyperthermia Hyperactivity
Outcomes: Ongoing

Cat, Cat (unknown), Female, 4.05 kilogram • Drug: MSK, Unknown, Dose: 0.16 Milligram per kilogram • Reactions: Hyperglycaemia • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-054116
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Weight: 4.050 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Dose: 0.16 Milligram per kilogram
Reactions Reported:
Hyperglycaemia
Outcomes: Outcome Unknown

Dog, ['Crossbred Canine/dog', 'Retriever - Labrador', 'Poodle - Medium size'], Female, 3 year, 12.338 kilogram • Drug: MSK, Unknown • Reactions: Lack of efficacy - NOS, Rubbing, Application site pain • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-056018
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 3.00 Year
  • Weight: 12.338 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Lack of efficacy - NOS Rubbing Application site pain
Outcomes: Ongoing

Cat, Domestic Shorthair, Male, 20 week, 3 kilogram • Drug: MSK, Unknown, Dose: 0.05 mL per animal • Reactions: Dysphoria, Sedation, Decreased blood urea nitrogen (BUN) or creatinine, Intentional misuse • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-053968
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 20.00 Week
  • Weight: 3.000 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Dose: 0.05 mL per animal
Reactions Reported:
Dysphoria Sedation Decreased blood urea nitrogen (BUN) or creatinine Intentional misuse
Outcomes: Outcome Unknown

Dog, Bulldog - French, Female, 10 year, 15.876 kilogram • Drug: MSK, Injection, Intramuscular, Dose: 0.10 mL per dose, Frequency: 1 per day • Reactions: Vomiting, Regurgitation, Not eating, Tiredness (lethargy), Not urinating… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-053925
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 10.00 Year
  • Weight: 15.876 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Form: Injection
  • Dose: 0.10 mL per dose
  • Frequency: 1 per day
Reactions Reported:
Vomiting Regurgitation Not eating Tiredness (lethargy) Not urinating Not defecating Swollen limb Local swelling Dull Elevated temperature Weakness Lying down Pain NOS Monocytosis Eosinopenia White blood cell disorder NOS Elevated alanine aminotransferase Elevated serum alkaline phosphatase Hypochloraemia Elevated creatinine Hyperphosphataemia Bruising Tachycardia Tachypnoea Panting Local erythema Wound Application site discharge NOS Application site bleeding Dry mucous membrane Unwell Purulent lesion Bacterial skin infection NOS Skin inflammation NOS Skin textural change
Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Female, 6 month, 3.45 kilogram • Drug: MSK, Intramuscular, Dose: 0.07 mL per animal • Reactions: Application site hair loss, Pyoderma • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-051014
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 6.00 Month
  • Weight: 3.450 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Dose: 0.07 mL per animal
Reactions Reported:
Application site hair loss Pyoderma
Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Female, 11.5 year, 4 kilogram • Drug: MSK, Intramuscular, Dose: 0.10 mL per animal • Reactions: Hyperactivity, Restlessness, Pacing, Not eating, Mydriasis… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-049844
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 11.50 Year
  • Weight: 4.000 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Dose: 0.10 mL per animal
Reactions Reported:
Hyperactivity Restlessness Pacing Not eating Mydriasis Drooling
Outcomes: Ongoing

Dog, Dog (other), Male, 8 year, 7.711 kilogram • Drug: MSK, Solution, Unknown, Frequency: 1 per day • Reactions: Overdose, Tarry or black stool, Oral bleeding, Haematemesis, Dehiscence… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-052403
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 8.00 Year
  • Weight: 7.711 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Solution
  • Frequency: 1 per day
Reactions Reported:
Overdose Tarry or black stool Oral bleeding Haematemesis Dehiscence Death Bradycardia Decreased haematocrit
Outcomes: Died

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.